Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells.

Mayr C, Kofler DM, Büning H, Bund D, Hallek M, Wendtner CM.

Blood. 2005 Nov 1;106(9):3223-6. Epub 2005 Jul 12.

2.

Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.

Biagi E, Dotti G, Yvon E, Lee E, Pule M, Vigouroux S, Gottschalk S, Popat U, Rousseau R, Brenner M.

Blood. 2005 Mar 15;105(6):2436-42. Epub 2004 Nov 9.

3.

CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes.

Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM.

Exp Hematol. 2007 Jun;35(6):920-30.

PMID:
17533046
5.

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ.

Blood. 2000 Nov 1;96(9):2917-24.

6.

Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.

Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6916-23.

7.

Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.

Gitelson E, Hammond C, Mena J, Lorenzo M, Buckstein R, Berinstein NL, Imrie K, Spaner DE.

Clin Cancer Res. 2003 May;9(5):1656-65.

8.

Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.

Romano C, De Fanis U, Sellitto A, Dalla Mora L, Chiurazzi F, Giunta R, Rotoli B, Lucivero G.

Leuk Lymphoma. 2003 Nov;44(11):1963-71.

PMID:
14738151
10.

Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity.

Schattner EJ, Mascarenhas J, Reyfman I, Koshy M, Woo C, Friedman SM, Crow MK.

Blood. 1998 Apr 15;91(8):2689-97.

11.

Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.

Takahashi S, Rousseau RF, Yotnda P, Mei Z, Dotti G, Rill D, Hurwitz R, Marini F, Andreeff M, Brenner MK.

Hum Gene Ther. 2001 Apr 10;12(6):659-70.

PMID:
11426465
12.

Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.

Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M, Wendtner CM.

Blood. 2005 Feb 15;105(4):1566-73. Epub 2004 Oct 7.

13.

T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy.

Krackhardt AM, Harig S, Witzens M, Broderick R, Barrett P, Gribben JG.

Blood. 2002 Jul 1;100(1):167-73.

14.

Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma.

Takahashi S, Yotnda P, Rousseau RF, Mei Z, Smith S, Rill D, Younes A, Brenner MK.

Cancer Gene Ther. 2001 May;8(5):378-87.

15.
16.

Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.

Knippertz I, Hesse A, Schunder T, Kämpgen E, Brenner MK, Schuler G, Steinkasserer A, Nettelbeck DM.

J Immunother. 2009 Jun;32(5):524-38. doi: 10.1097/CJI.0b013e3181a28422.

PMID:
19609245
17.

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22.

Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F, Ruffing N, Montagna L, Piccoli P, Chilosi M, Caligaris-Cappio F.

Eur J Immunol. 2002 May;32(5):1403-13.

18.

Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer.

Noguchi M, Imaizumi K, Kawabe T, Wakayama H, Horio Y, Sekido Y, Hara T, Hashimoto N, Takahashi M, Shimokata K, Hasegawa Y.

Cancer Gene Ther. 2001 Jun;8(6):421-9.

19.

Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate.

Suresh K, Fraser G, Scheid E, Leber B, Gauldie J, Foley R.

Leuk Lymphoma. 2006 Feb;47(2):297-306.

PMID:
16321861
20.

The potential of gene transfer into primary B-CLL cells using recombinant virus vectors.

Wendtner CM, Kofler DM, Mayr C, Bund D, Hallek M.

Leuk Lymphoma. 2004 May;45(5):897-904. Review.

PMID:
15291346

Supplemental Content

Support Center